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Abstract
Background: Gemcitabine is currently the standard chemotherapy for the adjuvant treatment of pancreatic cancer.
This chemotherapeutic agent is generally well-tolerated, myelosuppression and gastrointestinal toxicity being common
side effects. Nevertheless, gemcitabine-induced pulmonary toxicity has been rarely reported. Despite its low incidence,
the spectrum of pulmonary injury is wide, including potentially fatal conditions.
We report a case of acute interstitial pneumonia related to gemcitabine, completely solved with Imatinib Mesylate (IM).
Case presentation: The patient was a 69-year-old man, who developed a hypoxemic respiratory distress during
adjuvant treatment with gemcitabine for stage IIA pancreatic cancer. The nonspecific diffuse alveolar involvement
found on computed tomography (CT), together with the negative tests for infectious aetiology and the continuing
severe respiratory failure despite a long course of broad-spectrum therapy, suggested gemcitabine-induced acute
pneumonia as the most likely diagnosis.
Thus, after the failure of steroids and all other conventional therapies, the patient was treated with imatinib mesylate
on the basis of its activity in the management of graft-versus-host-induced lung fibrosis. A follow-up CT scan of chest
one month later showed complete resolution of pneumonia.
Conclusion: Despite the low frequency of serious pulmonary toxicity, gemcitabine widespread use warns clinicians to
consider this life-threatening toxicity. The favourable clinical outcome with IM treatment was remarkable, warranting
additional study of IM in the treatment of lung fibrosis.
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Background
Pancreatic cancer is one of the most fatal malignancies
worldwide, with an annual incidence rate almost identi-
cal to the mortality rate; being radical surgical resection
the only chance of cure although with high recurrence
rates [1].
An improvement in overall survival of patients submit-
ted to radical surgery is provided by adjuvant treatment
with gemcitabine or bolus 5-fluorouracil, with no differ-
ences in effectiveness between the two, but a better
safety profile of gemcitabine [2]. The most common
gemcitabine dose-limiting toxicity is myelosuppression,
whereas pulmonary toxicity has been reported in less
than 10 % of patients [3].
We report the case of a patient who developed an
acute gemcitabine induced acute interstitial pneumonia
and who was completely solved with imatinib mesylate
(IM) after the failure of conventional therapies.
Case presentation
Case
A 69-year-old man with a history of 75-pack year cigarette
smoking up to 2007 and a consequential centrilobular em-
physema presented with jaundice in September 2013.
After a thorough staging, he was subjected to pancreatico-
duodenectomy. The pathology report showed a mild
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differentiated pancreatic adenocarcinoma pT3, pN0, stage
IIA (TNM 7th Edition).
On January 2014 we began adjuvant chemotherapy
with gemcitabine 1,000 mg/m2 on days 1, 8, 15 every 28.
The treatment was well tolerated until 1 week after the
fourth cycle, when he developed fever up to 38 °C, pro-
ductive cough and exertional dyspnea. Despite a week of
oral levofloxacin (500 mg q24h), dyspnea worsened and
he was admitted to our inpatient ward. On examination
he was afebrile, with blood pressure of 140/80 mmHg,
pulse rate of 90 beats/min and respiratory rate of 22
breaths/min. His oxygen saturation was 85 % on room
air, which improved to 94 % after oxygen supplementa-
tion via a Venturi mask with a fraction of inspired oxy-
gen of 40 %. On auscultation, he presented diffuse
crackles involving lower lung fields. The WBC was
9,350/microL (reference range 4,500 to 10,000/microL),
haemoglobin 12.4 g/dl (reference range 13.8 to 17.2 g/dL)
and platelet count 360,000/L (reference range 150,000 to
400,000/L). Fibrinogen was 538 mg/dl (reference range <
400 mg/dl), and C-reactive protein level was 0.008 g/L
(reference range < 0.005 g/L). The remaining laboratory
tests were unremarkable. Room air arterial blood gas ana-
lysis revealed oxygen tension of 43 mmHg, carbon dioxide
tension of 41 mmHg, bicarbonate 27.7 mmol/L and pH of
7.45. The computed tomography (CT) scan showed sev-
eral ground-glass opacities, multiple areas of parenchymal
consolidation and air bronchogram in lower lobes and; left
pleural effusion and multiple enlarged hilar and medias-
tinal lymph nodes (Fig. 1). Altogether, the CT findings
were consistent with nonspecific diffuse alveolar involve-
ment; without signs of pulmonary oedema, embolism,
hypertension or tumor lymphangitic spread.
Sputum and blood cultures, CMV-DNA search,
streptococcus pneumoniae and legionella urinary antigen
and serum aspergillum antigen were negative. An empir-
ical broad-spectrum antimicrobial therapy was started,
involving Piperacillin/Tazobactam (4.5 g q6h), Moxiflox-
acin (400 mg q24h) and Fluconazole (100 mg q24h).
After 7 days, a chest CT showed increasing of parenchy-
mal consolidation and pleural effusion thus pneumologist
and infectious disease consultants suggested to change
therapy into meropenem (1 g q8h), vancomycin (500 mg
q6h), linezolid (600 mg q12h), acyclovir (800 mg q12h),
and voriconazole (200 mg q12h).
In spite of 14 days of broad-spectrum therapy,
patient’s respiratory condition continued to deteriorate,
a bronchoscopic assessment or lung biopsy was contra-
indicated, but a further CT scan showed significant
increase of parenchymal consolidation and ground-glass
areas predominantly in lower lobes, consistent with
ongoing pneumonia (Fig. 2).
Considering the CT scan, the negative tests for infec-
tious aetiology and the continuing severe respiratory fail-
ure despite a total of 22 days of broad-spectrum therapy,
gemcitabine-induced acute pneumonia was considered
to be the most likely diagnosis.
Seven days after the start of systemic methylpredniso-
lone 2 mg/kg/die, however, the respiratory condition
remained critical, with PaO2 of 65.2 mmHg on arterial
blood gases in 60 % mist mask ventilation (15 l/min).
Therefore, on the basis of IM activity in graft-versus-
host–induced lung fibrosis treatment, and our previous
experience in a similar condition we asked patient con-
sent and started therapy with IM 100 mg daily [4]. After
4 days the clinical condition and respiratory function
significantly improved, allowing the reduction of oxygen
and steroid therapy until the complete weaning 10 days
after, and the discontinuation of IM after 1 month.
Due to gemcitabine-induced pulmonary toxicity the
adjuvant treatment was discontinued. CT scans after
one (Fig. 3) and 5 months showed complete reso-
lution of the alveolar opacities. At the most recent
follow-up, the patient is alive without evidence of
Fig. 1 Chest CT scan image obtained at the time of clinical presentation with respiratory symptoms reveals nonspecific diffuse
alveolar involvement
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pancreatic disease, with a Karnofsky performance
status of 100 %.
Discussion
Gemcitabine-induced pulmonary toxicity is a relatively
uncommon complication, associated with significant
morbidity and mortality [3, 5]. Moreover the incidence
appears to be underestimated, since risk factors are un-
settled and isolated CT findings inadequate to make the
diagnosis [6].
The spectrum of respiratory toxicity varies from mild
dyspnea (25 %) to a form of fatal acute respiratory dis-
tress syndrome–like picture (0.3 %) [7, 8]. Belknap et al.
reviewed data on clinical characteristics of gemcitabine-
induced pulmonary toxicity identifying most frequent
symptoms in dyspnea (70 %), fever (35 %), and pulmon-
ary infiltrate (21.9 %); with a median time to the diagno-
sis of 48 days after initiation of gemcitabine [9].
The exact pathogenesis of lung injury is not known,
however gemcitabine seems to induce the release of pro-
inflammatory cytokines causing deregulation of tissue re-
pair [10, 11]. Specifically, in idiopathic pulmonary fibrosis,
an enhanced expression of platelet-derived growth factor
receptor (PDGFR) and tumor growth factor (TGF)-beta
induces proliferation and transformation of extracellular
matrix in idiopathic pulmonary fibrosis [12]. This
phenomenon leads to the replacement of normal lung by
cystic spaces separated by thick fibrous tissue until pro-
gressive cleavage of alveolar structures. In animal models,
the same receptors are involved in bleomicine-induced
pulmonary fibrosis, which is a pathologic condition that
closely resembles the final lung damage observed in
gemcitabine-induced pulmonary toxicity.
The management of patients affected by idiopathic
pulmonary fibrosis is notably challenging, due to the
lacking of a current recommended treatment. Multiple
drugs have been tested for pulmonary fibrosis treatment
and evidence both for and against their use has alterned
over the years. Yet, until recently, this was essentially an
untreatable disease. According to existing guidelines, at
present there are essentially two therapies that have
shown some efficacy. Pirfenidone, an orally administered
pyridone compound with a supposable effect on TGF-β
production, reduced disease progression and increased
survival in this group of patients. Similarly, Nintedanib,
a multikinase inhibitor, decelerated disease progression
Fig. 2 Chest CT scan image after 14 days of broad-spectrum therapy with deteriorating respiratory condition: increase in size and number of the
parenchymal consolidation and ground-glass areas, consistent with ongoing pneumonia
Fig. 3 Chest CT scan image obtained 1 month after the start of imatinib mesylate demonstrates resolution of ground-glass opacities and
parenchymal consolidation
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in a comparable cluster. This is a notably breakthrough
for patients and physicians alike; nevertheless, the results
in these trials were based on clinical outcomes, without
a definitively demonstration of per se reduction in lung
fibrosis [13].
IM is a specific receptor tyrosine-kinase-inhibitor of
both isoforms of PDGFR, approved for chronic myeloge-
nous leukaemia and gastrointestinal stromal tumours.
The recognized role of PDGFR and TGF-β pathways in
idiopathic pulmonary fibrosis pathogenesis led to subse-
quent investigations assessing IM as a potential inhibitor
of lung fibrosis [14]. Hence IM was identified as a potent
inhibitor of lung fibroblast–myofibroblast and extracel-
lular matrix proliferation, showing to prevent
bleomycin-induced pulmonary fibrosis in mice.
The hypothesis of treating lung fibrosis using IM has
been evaluated in a phase II randomized placebo-
controlled trial. Notwithstanding, patients with idio-
pathic pulmonary fibrosis treated with IM 600 mg once
daily, despite a significant increase of PaO2, did not
receive significant survival improvement [15]. However
it should be emphasized the profoundly different context
from our case: patients with idiopathic fibrosis included
in that trial had a mild-moderate fibrosis, diagnosed like-
wise 36 months before, with PaO2-values above 60 mmHg.
These assumptions encouraged us to test a low-
toxicity profile drug such as IM in a patient whose
rapidly worsening clinical condition had been refractory
to previously therapies.
Conclusions
As discussed above, gemcitabine-induced pulmonary
toxicity is a diagnosis of exclusion and several other
respiratory diseases have to be ruled out. Nevertheless,
this condition needs to be promptly recognized because
it may be fatal [16]. Therefore, despite the infrequency
of this complication, gemcitabine widespread use warns
clinicians to consider this life-threatening toxicity.
The description of a few cases of favourable clinical
outcome in literature, including the complete response
of our case report, suggests that additional study of IM
in the treatment of lung fibrosis are needed, also consid-
ering the mentioned lack of efficient treatments.
It is clear that, even though only a randomised-
controlled-trial can provide a formal and statistically
valid demonstration of the role of IM in this circum-
stance, such a study is difficult to conceive in a rapidly
fatal disease.
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